The PennZone

International Collaboration Aims to Ensure More Equitable Access to Transformative Personalized Cancer Therapy

PHILADELPHIA, May 23, 2022 /PRNewswire/ -- Penn Medicine and Children's Hospital of Philadelphia (CHOP), who together pioneered the research and development of the world's first personalized cellular therapy for cancer — also known as CAR T cell therapy — have announced plans with Costa Rica's CCSS, or the Caja Costarricense de Seguro Social (Social Security Program), to facilitate CAR T research in Costa Rica. The effort is a step toward global equity in clinical research opportunities involving the use of CAR T cell therapies, which represent a leading-edge approach to cancer care not widely available across the world.

More on The PennZone

• Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
• Stratum Nutrition's OVOLUX™ Named 2025 "Collagen Ingredient of the Year" by Beauty Innovation Awards
• Sons of Liberty Museum Unveils "America at 250" Mobile Exhibit on Veterans Day 2025
• Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
• Bent Danholm Releases New Video Breaking Down the Rising Debate Over 50-Year Mortgages

---

Show All News | Report Violation